List of Excipients in Branded Drug TIMOLOL HEMIHYDRATE

Generic Drugs Containing TIMOLOL HEMIHYDRATE

Company	Ingredient	NDC	Excipient
Somerset Therapeutics LLC	timolol hemihydrate	70069-516	BENZALKONIUM CHLORIDE
Somerset Therapeutics LLC	timolol hemihydrate	70069-516	POTASSIUM SORBATE
Somerset Therapeutics LLC	timolol hemihydrate	70069-516	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in TIMOLOL HEMIHYDRATE?

# Of NDCs	Excipient
2	BENZALKONIUM CHLORIDE
1	POTASSIUM SORBATE
1	SODIUM CHLORIDE

Timolol Hemihydrate Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Timolol hemihydrate is a mature ophthalmic beta-blocker active pharmaceutical ingredient used primarily to reduce intraocular pressure in glaucoma and ocular hypertension. The commercial opportunity is no longer based on basic molecule exclusivity. It is concentrated in preservative-free delivery, multidose container systems, improved ocular residence, combination products, manufacturing efficiency, and differentiated tolerability.

Timolol hemihydrate is marketed in ophthalmic solutions and gel-forming products. Timolol maleate is the more common salt form in U.S. products, including many generic ophthalmic solutions and fixed combinations. The two forms cannot be treated as interchangeable from a formulation, regulatory, or intellectual-property perspective because salt selection affects concentration, pH, osmolality, crystallization, and labeling.

What is timolol hemihydrate and how is it used?

Timolol is a nonselective beta-adrenergic receptor antagonist. Ophthalmic administration reduces aqueous humor production and lowers intraocular pressure. FDA-approved indications include ocular hypertension and open-angle glaucoma, subject to product labeling. Timolol ophthalmic products are generally available as solutions, gel-forming solutions, and, in some markets, preservative-free presentations.

Attribute	Timolol hemihydrate
Therapeutic class	Ophthalmic nonselective beta-blocker
Primary uses	Open-angle glaucoma and ocular hypertension
Administration	Topical ophthalmic
Common strengths	0.25% and 0.5%
Principal dosage forms	Ophthalmic solution and gel-forming solution
Common comparator salt	Timolol maleate
Regulatory category	Small-molecule drug
Biosimilar exposure	None
Primary commercial issue	Differentiated delivery and tolerability rather than molecule exclusivity

FDA labeling warns that ophthalmic timolol can be systemically absorbed and may produce systemic beta-blocking effects, including bradycardia, hypotension, bronchospasm, and worsening cardiac failure in susceptible patients (U.S. Food and Drug Administration [FDA], 2017a; FDA, 2017b).

What excipients are used in timolol hemihydrate ophthalmic products?

Excipient selection must control pH, tonicity, chemical stability, microbial quality, drop delivery, and ocular comfort. The formulation target is a clear, sterile product with consistent timolol content throughout shelf life.

Typical excipient categories include:

Formulation function	Common excipient classes	Commercial purpose
Buffering	Phosphate, citrate, borate systems	Maintain pH during storage and use
Tonicity adjustment	Sodium chloride, boric acid, polyols	Reduce ocular discomfort
Chelation	Disodium edetate	Limit metal-catalyzed degradation
Viscosity enhancement	Hydroxyethylcellulose, hypromellose, carbomers, polyvinyl alcohol	Increase residence time and reduce drainage
Preservation	Benzalkonium chloride, polyquaternium-1, stabilized oxychloro complex	Control microbial growth in multidose packaging
Solubilization and wetting	Surfactants or co-solvent systems, where justified	Support clarity and uniformity
Container compatibility	Low-adsorption polymers and compatible elastomers	Limit loss of active ingredient or preservative

The exact excipient system varies by product and salt form. Betimol labeling identifies timolol hemihydrate as the active ingredient and includes inactive ingredients such as sodium phosphate buffers, sodium hydroxide or hydrochloric acid for pH adjustment, and benzalkonium chloride in preserved presentations (FDA, 2017b). Timoptic and several generic products use timolol maleate rather than timolol hemihydrate (FDA, 2017a; National Library of Medicine, 2024a).

How should an excipient strategy address pH and chemical stability?

The formulation should establish a pH range that balances timolol solubility, chemical stability, ocular tolerability, and preservative performance. Excessive pH adjustment can increase irritation, while an overly acidic or weakly buffered system can create drift during storage.

A practical development strategy is:

1. Screen phosphate, citrate, and borate buffers across a controlled pH range.
2. Measure assay, related substances, clarity, osmolality, and pH after accelerated and long-term storage.
3. Test compatibility with the intended bottle, tip, cap, and elastomer.
4. Evaluate preservative concentration after contact with the container.
5. Assess drop size and delivered dose after aging.

Chelation can be useful where trace metals accelerate degradation, but disodium edetate must be evaluated for compatibility with preservatives, container materials, and ocular tolerability. Buffer selection also has commercial relevance. A low-buffer-capacity product can reduce irritation caused by pH mismatch with the tear film, but it may have less resistance to pH drift during repeated use.

Which preservatives create the largest commercial opportunity?

Benzalkonium chloride is widely used in ophthalmic products because it is effective, familiar to regulators, and compatible with many multidose systems. Its chronic-use profile creates an opportunity for preservative-free or low-irritation alternatives.

Repeated exposure to benzalkonium chloride has been associated with ocular-surface irritation and changes to the tear film, particularly in patients receiving long-term glaucoma therapy or multiple preserved eye drops (European Medicines Agency, 2009). This creates a commercial opening for:

• Unit-dose preservative-free timolol hemihydrate.
• Multidose bottles using a preservative-free valve or filtering system.
• Alternative preservatives such as polyquaternium-1, where supported by the formulation and regulatory package.
• Reduced-preservative products targeted at ocular-surface disease and polypharmacy.
• Combination products designed to reduce the total number of daily preserved instillations.

The strongest product differentiation is likely to come from a preservative-free multidose system rather than from a new buffer alone. Packaging, microbial robustness, extractables and leachables, pump performance, and in-use stability become central development issues.

What formulations are protected by patents or regulatory exclusivity?

Basic timolol composition-of-matter protection is no longer a meaningful barrier in the United States. Timolol was commercialized decades ago, and conventional ophthalmic solutions are mature generic products.

Potentially protectable subject matter includes:

Subject matter	Patent or regulatory value
Preservative-free multidose delivery	Potential formulation and device claims
Gel-forming solution	Potential viscosity, polymer, or release-profile claims
Specific salt or hydrate form	Potential solid-state or manufacturing claims if novel and non-obvious
Extended ocular residence	Potential formulation and method-of-use claims
Fixed combinations	Potential composition and dosing claims
Container-closure system	Potential device, valve, or microbial-barrier claims
Manufacturing process	Potential process and impurity-control claims
Patient subgroup or dosing regimen	Potential method-of-use protection, subject to eligibility and enforceability

A patent strategy based only on timolol hemihydrate as an active ingredient would be weak because the underlying pharmacology and ophthalmic use are established. A stronger estate would combine formulation claims, container-system claims, manufacturing claims, and narrowly drafted method-of-use claims.

What is the Orange Book status of timolol hemihydrate?

FDA-approved timolol products are listed by product-specific application and active ingredient. Orange Book treatment depends on the approved product, strength, dosage form, and applicant rather than on the ingredient name alone (FDA, 2024).

The commercial implications are:

• Conventional timolol ophthalmic products generally face abbreviated new drug application competition.
• A new timolol hemihydrate product may require an ANDA, a 505(b)(2) application, or, in some cases, a full NDA depending on the formulation and reference product.
• A formulation materially different from existing reference products may create regulatory complexity even when the active ingredient is well established.
• Orange Book-listed patents, if any, must be assessed at the individual reference-product level.
• FDA approval does not itself establish freedom to operate for patents covering devices, manufacturing processes, or foreign markets.

Product-specific review of Drugs@FDA, the Orange Book, and FDA-approved labeling is required because timolol hemihydrate and timolol maleate are represented through different products and application histories (FDA, 2024; National Library of Medicine, 2024a).

When does timolol lose exclusivity, and what generic entry risks exist?

Timolol’s fundamental market exclusivity has expired. The relevant generic-entry risk is therefore not an approaching loss of exclusivity date. It is ongoing price pressure from established generic manufacturers.

Paragraph IV challenges

Paragraph IV activity is relevant when a generic applicant challenges an Orange Book-listed patent for a branded product. For mature conventional timolol products, the principal competitive pathway is usually ANDA substitution or generic launch after approval, not a major future Paragraph IV event.

For a new differentiated product, risk would depend on:

• Whether the sponsor lists formulation or device patents.
• Whether generic applicants can design around those claims.
• Whether the reference product qualifies for ANDA substitution.
• Whether a 30-month stay is triggered by patent litigation.
• Whether the product is approved under 505(b)(2), which can create a different patent-certification profile.

Generic launch scenarios

Scenario	Likely commercial effect
Conventional preserved solution	Rapid price competition and limited differentiation
Preservative-free unit-dose product	Moderate protection through manufacturing cost, packaging, and brand positioning
Preservative-free multidose device	Higher technical barrier and stronger potential differentiation
Gel-forming product	Moderate barrier based on polymer system and performance data
Fixed combination	Higher development and substitution complexity
Depot or sustained-release ocular system	Greater clinical and regulatory risk, with potentially stronger patent value

How strong is the patent estate for timolol hemihydrate?

The patent estate is weak for the base molecule and conventional ophthalmic solution. It can be commercially stronger for a new delivery platform.

A practical strength assessment is:

Asset type	Relative patent strength	Main vulnerability
Timolol active ingredient	Low	Expired prior art
Timolol hemihydrate conventional solution	Low to moderate	Extensive formulation prior art
Specific buffer and preservative combination	Low to moderate	Obviousness and design-around risk
Gel-forming formulation	Moderate	Polymer substitution and overlap with prior art
Preservative-free multidose device	Moderate to high	Device prior art and engineering workarounds
Sustained-release ocular insert or depot	Moderate to high	Clinical performance and enablement requirements
Manufacturing impurity-control process	Moderate	Process non-infringement may be difficult to detect
Fixed combination with another glaucoma drug	Moderate	Prior-art combinations and regulatory substitution

The most valuable claims are likely to be claims that connect formulation composition with measurable performance, such as sustained ocular residence, reduced dosing frequency, preservative-free microbial protection, or improved tolerability. Broad claims to “timolol in an ophthalmic solution” are unlikely to provide durable protection.

What FDA regulatory pathway is most suitable for a new product?

The pathway depends on the degree of formulation and device differentiation.

ANDA

An ANDA is suitable when the product can demonstrate bioequivalence and pharmaceutical equivalence to an approved reference product. This pathway supports lower development cost but limits differentiation and often leads to generic pricing.

505(b)(2) NDA

A 505(b)(2) application may be suitable for a new timolol hemihydrate formulation, delivery system, concentration, dosing regimen, or combination that relies partly on existing FDA findings but requires new investigations. This pathway can support three-year clinical exclusivity for certain approved changes, but the exclusivity is limited and does not replace patent protection.

Full NDA

A full NDA would be appropriate where the product depends on substantial new clinical evidence or cannot rely sufficiently on existing findings. It would be the most expensive route and would require a clear clinical advantage or commercial rationale.

FDA guidance for ophthalmic drug products places significant emphasis on sterility, container-closure integrity, particulate control, microbiological quality, stability, and dose delivery (FDA, 2016).

Which licensing deals and partnerships are commercially relevant?

Publicly visible commercial activity around timolol has historically centered on product acquisition, generic supply, ophthalmic manufacturing, and branded ophthalmology portfolios rather than high-value licensing of the timolol molecule.

Potential transaction targets include:

• Licensing a preservative-free multidose bottle platform.
• Contract manufacturing of sterile ophthalmic solutions.
• Regional rights for established timolol products.
• Co-development of timolol fixed combinations.
• Acquisition of a glaucoma product with an existing ophthalmology sales force.
• Supply agreements for pharmaceutical-grade timolol hemihydrate and sterile filling.
• Device partnerships for valve-based or metered-dose ophthalmic delivery.

The commercial value of a deal would depend more on device ownership, regulatory status, manufacturing capacity, and payer positioning than on the active ingredient.

What manufacturing and IP barriers affect commercialization?

Sterile ophthalmic manufacturing is the main operational barrier. A commercially viable product requires validated sterilization or aseptic processing, low particulate burden, container-closure integrity, extractables and leachables control, and reliable drop delivery.

Key technical risks include:

• Timolol adsorption to plastic or elastomer components.
• Preservative depletion through container interaction.
• pH drift during storage.
• Crystallization or haze formation.
• Variable drop size caused by viscosity changes.
• Microbial ingress after repeated opening.
• Incompatibility between polymers and the active salt.
• Scale-up changes that alter viscosity, osmolality, or delivered dose.

Process patents may be valuable because manufacturing know-how can be difficult for competitors to reproduce even when the final formulation appears simple. Their practical value is limited if infringement cannot be detected from the marketed product.

How does timolol hemihydrate compare with timolol maleate?

Issue	Timolol hemihydrate	Timolol maleate
Commercial presence	Established but narrower in U.S. products	Broad generic and branded presence
Formulation focus	Ophthalmic solution and gel systems	Ophthalmic solution and fixed combinations
Regulatory competition	Product-specific	Extensive generic competition
Salt-form opportunity	Potential differentiation through hydrate and formulation control	More established reference-product landscape
Patent opportunity	Delivery, device, and process claims	Delivery, device, and combination claims
Substitution risk	Depends on approved reference and labeling	High in conventional generic segments
Best commercial strategy	Preservative-free or device-enabled product	Differentiated combination or ocular-surface positioning

Timolol hemihydrate should not be positioned as a wholly new pharmacologic product. Its strongest commercial rationale is an improved delivery system that reduces preservative exposure, dosing burden, or administration variability.

What revenue exposure and market opportunities exist?

Revenue exposure for conventional timolol is high because the product is mature, inexpensive, and widely substitutable. A new product can improve margins only by addressing a defined clinical or operational problem.

The most attractive segments are:

1. Preservative-free products for chronic glaucoma patients.
2. Multidose systems that avoid unit-dose waste.
3. Combination products that reduce administration burden.
4. Gel-forming products requiring less frequent dosing.
5. Regional markets with limited access to modern ocular-surface-friendly formulations.
6. Contract manufacturing and private-label supply.
7. Hospital and specialty-pharmacy channels where device performance and sterility are valued.

A premium product must demonstrate a practical benefit, such as reduced ocular-surface toxicity, fewer daily doses, lower waste, more consistent dosing, or improved adherence. A higher price without a measurable delivery or tolerability advantage would face substitution pressure.

Key Takeaways

• Timolol hemihydrate is a mature small-molecule ophthalmic drug with no biosimilar risk.
• Basic molecule and conventional-use protection are no longer meaningful commercial barriers.
• Timolol maleate remains a major comparator and generic competitor.
• The best excipient strategy combines pH control, tonicity adjustment, chemical stabilization, low irritation, and container compatibility.
• Benzalkonium chloride creates a commercial opening for preservative-free products.
• The strongest product opportunity is a preservative-free multidose system with credible microbial protection.
• Formulation, device, manufacturing, and performance patents are more valuable than active-ingredient claims.
• ANDA development supports cost-efficient generic entry; 505(b)(2) supports differentiated formulations and devices.
• Manufacturing capability, sterile filling, packaging, and regulatory execution may create more practical barriers than the active ingredient.
• Commercial success depends on reducing preservative exposure, dosing frequency, administration variability, or total treatment burden.

FAQs

Is timolol hemihydrate the same as timolol maleate?

No. They are different salt or solid-state forms of timolol and require product-specific formulation and regulatory assessment. Their approved products, concentrations, excipients, and labeling may differ.

Can a preservative-free timolol hemihydrate product obtain patent protection?

Yes, but protection would more likely cover the formulation, container system, microbial-control architecture, manufacturing process, or performance characteristics rather than the underlying timolol molecule.

Is timolol hemihydrate suitable for a 505(b)(2) application?

It can be, particularly where the product uses a novel delivery system, dosing regimen, gel-forming platform, combination, or other change that requires new supporting data.

What is the highest-value excipient opportunity for timolol ophthalmic products?

The highest-value opportunity is an excipient and packaging system that enables preservative-free multidose delivery while maintaining sterility, dose uniformity, chemical stability, and patient comfort.

Does timolol hemihydrate face biosimilar competition?

No. Timolol hemihydrate is a small-molecule drug. Competition comes from generic drugs, alternative salt forms, fixed combinations, and differentiated ophthalmic delivery systems.

References

1. European Medicines Agency. (2009). Questions and answers on benzalkonium chloride used as an excipient in medicinal products for human use. EMA.

2. National Library of Medicine. (2024a). DailyMed: Timolol ophthalmic products. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2016). Ophthalmic drug products for topical application: Quality considerations. FDA.

4. U.S. Food and Drug Administration. (2017a). TIMOPTIC label. FDA.

5. U.S. Food and Drug Administration. (2017b). BETIMOL label. FDA.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.